CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Jami
Nachtsheim to its Board of Directors. Ms. Nachtsheim currently serves on
the Board at Intuitive Surgical, the global market leader in
robotic-assisted minimally invasive surgical systems. Ms. Nachtsheim
brings nearly four decades of commercial and marketing leadership
experience to the Cerus Board.
In connection with the appointment of Ms. Nachtsheim, the Company also
announced that Dr. Laurence Corash has chosen not to stand for
reelection to the Board of Directors at the Company’s 2019 Annual
Stockholder Meeting. Dr. Corash, a founder of Cerus, has served on
Cerus’ Board since December 2002 and will continue in his role as Chief
Scientific Officer, as a member of the Company’s senior executive team,
and leader of Cerus’ government relations program.
“We are delighted to welcome Jami to Cerus’ Board of Directors,” said
Daniel Swisher, Chair of the Board. “Jami’s extensive experience in
creating global brands and executive oversight of technology driven
growth companies provides another valuable perspective as Cerus
continues to execute and grow.”
“In addition, on behalf of the Board, I want to thank Larry for his
significant contributions on the Board over the past sixteen years, and
we are grateful for his continuing service on the Company’s executive
team. His scientific leadership in the field of transfusion medicine
innovation and unwavering commitment to improving blood safety and
availability for patients has guided our decision making since his
founding of the company in 1992,” continued Swisher.
“Cerus is transforming transfusion medicine and is well positioned to
establish INTERCEPT as the global standard of care for transfused blood
components,” said Ms. Nachtsheim. “I am looking forward to working with
Cerus management to help the team capitalize on the significant growth
potential in their business and to build an enduring brand.”
Ms. Nachtsheim has served on the Board of Intuitive Surgical since April
2017. Ms. Nachtsheim’s other board experiences include FEI Company from
2010 to 2016, Affymetrix from 2009 to 2016 and as chair from 2015 to
2016, and Southwall Technologies from 2003 to 2011. Earlier in her
career, Ms. Nachtsheim served in a variety of senior leadership roles at
Intel Corporation from 1980 until 2000, including corporate vice
president of the sales and marketing group and director of worldwide
marketing responsible for the Intel Inside® program.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190305005921/en/
Tim Lee – Investor Relations Director
Cerus Corporation
925-288-6137
Source: Cerus Corporation